Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to demonstrate that a fixed dose combination of telmisartan 80 mg plus
hydrochlorothiazide (HCTZ) 12.5 mg (FDC 80/12.5) is superior to telmisartan 80 mg (Telm 80)
alone in patients who failed to respond adequately to Telm 80 monotherapy in lowering seated
trough diastolic blood pressure (DBP) after eight weeks of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Hydrochlorothiazide Telmisartan Telmisartan, hydrochlorothiazide drug combination